These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Human equivalent doses of platelet inhibitors and experimental atherosclerosis. Mittal SR; Mathur AK; Tandon R Int J Cardiol; 1990 May; 27(2):275-6. PubMed ID: 2365516 [TBL] [Abstract][Full Text] [Related]
5. Dose antiplatelet agents; the relationship among side effects, and antithrombotic effectiveness. Hirsh J; Fuster V; Salzman E Chest; 1986 Feb; 89(2 Suppl):4S-10S. PubMed ID: 3510829 [No Abstract] [Full Text] [Related]
6. [Effect of sulfinpyrazone on the platelet function and in experimental thrombosis]. Haas S; Ketterl R; Blümel G Fortschr Med; 1981 Jan; 99(4):113-8. PubMed ID: 7274948 [TBL] [Abstract][Full Text] [Related]
7. [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. Oelz O Schweiz Med Wochenschr; 1979 Mar; 109(10):348-53. PubMed ID: 424707 [TBL] [Abstract][Full Text] [Related]
8. Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets. Eichner ER Am J Med; 1984 Sep; 77(3):513-23. PubMed ID: 6383036 [TBL] [Abstract][Full Text] [Related]
9. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. Philp RB; Francey I; Warren BA Haemostasis; 1978; 7(5):282-93. PubMed ID: 689491 [TBL] [Abstract][Full Text] [Related]
10. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Schumacher WA; Steinbacher TE; Heran CL; Megill JR; Durham SK Thromb Haemost; 1993 May; 69(5):509-14. PubMed ID: 8322273 [TBL] [Abstract][Full Text] [Related]
12. Prevention of thrombosis with antiplatelet drugs. Kahn SB Am Fam Physician; 1980 May; 21(5):166-8. PubMed ID: 7377074 [No Abstract] [Full Text] [Related]
13. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. Hanson SR; Harker LA; Bjornsson TD J Clin Invest; 1985 May; 75(5):1591-9. PubMed ID: 3923041 [TBL] [Abstract][Full Text] [Related]
14. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. de Gaetano G; Cerletti C; Bertelè V Lancet; 1982 Oct; 2(8305):974-7. PubMed ID: 6127469 [No Abstract] [Full Text] [Related]
15. Antiplatelet therapy (first of two parts). Weiss HJ N Engl J Med; 1978 Jun; 298(24):1344-7. PubMed ID: 651993 [No Abstract] [Full Text] [Related]
16. Antiplatelet drugs in the management of patients with thrombotic disorders. Harker LA Semin Thromb Hemost; 1986 Apr; 12(2):134-55. PubMed ID: 3016905 [No Abstract] [Full Text] [Related]
17. Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position. McNicol GP Lancet; 1980 Oct; 2(8197):736-8. PubMed ID: 6106840 [No Abstract] [Full Text] [Related]
18. Drug utilization review: dipyridamole plus aspirin antiplatelet therapy. Crisp CB; Garrard EA Hosp Formul; 1985 Nov; 20(11):1175-7, 1180-1, 1185. PubMed ID: 10274573 [TBL] [Abstract][Full Text] [Related]
19. Are agents affecting platelet functions clinically useful? Verstraete M Am J Med; 1976 Dec; 61(6):897-914. PubMed ID: 795299 [TBL] [Abstract][Full Text] [Related]